Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.
In clinical practice, there are individuals who have chronic low-grade hypomanic symptoms: high energy, need for less sleep than others, chronic optimism, and chronic risk-taking.
Chatbots engage youth with connection but pose serious risks, potentially harming mental health and fostering unhealthy attachments. Awareness and regulation are crucial.
New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.
Explore the complex interplay of genetics, environment, concussion, substance abuse, and inflammation in severe mental illnesses, revealing critical insights for prevention and treatment.